|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM33999522X |
| 003 |
DE-627 |
| 005 |
20231226004139.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202202169
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1133.xml
|
| 035 |
|
|
|a (DE-627)NLM33999522X
|
| 035 |
|
|
|a (NLM)35470476
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhang, Zhan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Reactive Oxygen Species Scavenging Nanomedicine for the Treatment of Ischemic Heart Disease
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 08.09.2022
|
| 500 |
|
|
|a Date Revised 08.09.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2022 The Authors. Advanced Materials published by Wiley-VCH GmbH.
|
| 520 |
|
|
|a Ischemic heart disease (IHD) is the leading cause of disability and mortality worldwide. Reactive oxygen species (ROS) have been shown to play key roles in the progression of diabetes, hypertension, and hypercholesterolemia, which are independent risk factors that lead to atherosclerosis and the development of IHD. Engineered biomaterial-based nanomedicines are under extensive investigation and exploration, serving as smart and multifunctional nanocarriers for synergistic therapeutic effect. Capitalizing on cell/molecule-targeting drug delivery, nanomedicines present enhanced specificity and safety with favorable pharmacokinetics and pharmacodynamics. Herein, the roles of ROS in both IHD and its risk factors are discussed, highlighting cardiovascular medications that have antioxidant properties, and summarizing the advantages, properties, and recent achievements of nanomedicines that have ROS scavenging capacity for the treatment of diabetes, hypertension, hypercholesterolemia, atherosclerosis, ischemia/reperfusion, and myocardial infarction. Finally, the current challenges of nanomedicines for ROS-scavenging treatment of IHD and possible future directions are discussed from a clinical perspective
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a cardiovascular disease
|
| 650 |
|
4 |
|a diabetes
|
| 650 |
|
4 |
|a hypercholesterolemia
|
| 650 |
|
4 |
|a hypertension
|
| 650 |
|
4 |
|a ischemia heart disease
|
| 650 |
|
4 |
|a nanomedicine
|
| 650 |
|
4 |
|a reactive oxygen species
|
| 650 |
|
7 |
|a Reactive Oxygen Species
|2 NLM
|
| 700 |
1 |
|
|a Dalan, Rinkoo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hu, Zhenyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Jiong-Wei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chew, Nicholas Ws
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Poh, Kian-Keong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tan, Ru-San
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Soong, Tuck Wah
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dai, Yunlu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ye, Lei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Xiaoyuan
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 34(2022), 35 vom: 26. Sept., Seite e2202169
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:34
|g year:2022
|g number:35
|g day:26
|g month:09
|g pages:e2202169
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202202169
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 34
|j 2022
|e 35
|b 26
|c 09
|h e2202169
|